We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
AVTX | Avalo Therapeutics Inc | 21.20 | 16.45 | 346.32% | 1,169,011 |
XLO | Xilio Therapeutics Inc | 2.00 | 1.36 | 212.99% | 2,097,727 |
BCG | Binah Capital Group Inc | 18.65 | 9.15 | 96.32% | 166,904 |
PIK | Kidpik Corporation | 5.27 | 2.00 | 61.16% | 1,803,927 |
PEGR | Project Energy Reimagined Acquisition Corporation | 11.58 | 2.92 | 33.72% | 353 |
KTRA | Kintara Therapeutics Inc | 0.115 | 0.0255 | 28.49% | 13,652,361 |
APVO | Aptevo Therapeutics Inc | 4.99 | 0.93 | 22.91% | 11 |
AKBA | Akebia Therapeutics Inc | 2.69 | 0.45 | 20.09% | 6,335,754 |
ATLX | Atlas Lithium Corporation | 17.80 | 2.88 | 19.30% | 6,356 |
JCSE | JE Cleantech Holdings Limited | 0.882 | 0.1419 | 19.17% | 10 |
BRKH | BurTech Acquisition Corporation | 13.00 | 2.00 | 18.18% | 533 |
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
Kidpik Corp. (NASDAQ: PIK) ("kidpik” or the "Company"), an online clothing subscription-based e-commerce company, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that is has regained full compliance with the Minimum Bid Price Requirement.
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,513.60 | 1,049.03 | 1.51% | 1.39T | 7,376,737,190 |
ETH | Ethereum | 3,577.61 | 77.55 | 2.22% | 430.05B | 3,937,733,128 |
USDT | Tether USD | 0.99949 | 0.00005 | 0.01% | 97.78B | 1,037,898,827 |
BNB | Binance Coin | 585.58 | 11.46 | 2.00% | 92.66B | 517,323,115 |
SOL | Solana | 184.94 | -1.18 | -0.63% | 81.71B | 1,821,036,200 |
STETH | stETH | 3,572.86 | 108.43 | 3.13% | 34.69B | 13,509,541 |
XRP | Ripple | 0.6208 | 0.0093 | 1.52% | 33.89B | 598,304,485 |
DOGE | Dogecoin | 0.22156 | 0.03138 | 16.51% | 31.13B | 2,190,603,403 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,500,108,899 |
ADA | Cardano | 0.651 | 0.0034 | 0.53% | 22.89B | 201,979,539 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions